About ChromaCode
ChromaCode is a company based in Carlsbad (United States) founded in 2012. ChromaCode has raised $95.02 million across 8 funding rounds from investors including Caltech, Shimadzu Corporation and Global Brain. The company has 46 employees as of December 31, 2022. ChromaCode offers products and services including HDPCR Technology, ChromaCode Cloud, and Reagent Kits. ChromaCode operates in a competitive market with competitors including NeuMoDx, Biofire Diagnostics, InDex Pharmaceuticals, Kryptos Biotechnologies and Quantalife, among others.
- Headquarter Carlsbad, United States
- Employees 46 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Chromacode, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$95.02 M (USD)
in 8 rounds
-
Latest Funding Round
$3.85 M (USD), Series C
Jan 30, 2025
-
Investors
Caltech
& 9 more
-
Employee Count
46
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ChromaCode
ChromaCode offers a comprehensive portfolio of products and services, including HDPCR Technology, ChromaCode Cloud, and Reagent Kits.
Multiplexing platform for DNA and RNA variants in oncology testing.
Cloud-based tool for data analysis and assay deployment in labs.
Kits for cost-effective genomic workflows in clinical settings.
People of ChromaCode
Unlock access to complete
Unlock access to complete
Funding Insights of ChromaCode
ChromaCode has successfully raised a total of $95.02M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $3.85 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series C — $3.8M
-
First Round
First Round
(01 Jul 2015)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series C - ChromaCode | Valuation |
investors |
|
| Jun, 2023 | Amount | Series C - ChromaCode | Valuation | Shimadzu Corporation , Global Brain |
|
| Dec, 2020 | Amount | Series C - ChromaCode | Valuation | Northpond Ventures |
Investors in ChromaCode
ChromaCode has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Caltech, Shimadzu Corporation and Global Brain.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global Brain is recognized as a venture capital firm supporting startups.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life sciences & tech sectors
|
Founded Year | Domain | Location | |
|
Growth & expansion stage VC firm invesing in the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by ChromaCode
Financial Statements - ChromaCode
Chromacode Comparisons
Competitors of ChromaCode
ChromaCode operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NeuMoDx, Biofire Diagnostics, InDex Pharmaceuticals, Kryptos Biotechnologies and Quantalife, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of a platform for low cost molecular testing
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic solutions for genetic condition detection are provided.
|
|
| domain | founded_year | HQ Location |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| domain | founded_year | HQ Location |
Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology.
|
|
| domain | founded_year | HQ Location |
Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease.
|
Latest news on Chromacode
Frequently Asked Questions about ChromaCode
ChromaCode was founded in 2012 and raised its 1st funding round 3 years after it was founded.
ChromaCode is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Paul Flook is the current CEO of ChromaCode.
ChromaCode is a funded company, having raised a total of $95.02M across 8 funding rounds to date. The company's 1st funding round was a Series C of $38.64M, raised on Jul 01, 2015.
As of Dec 31, 2022, the latest employee count at ChromaCode is 46.
ChromaCode was founded in 2012 and is headquartered in Carlsbad, United States. Operations focus on the biotechnology sector, where digital molecular biology analytics are provided for disease management. A proprietary platform is utilized alongside existing qPCR instruments to expand multiplexing capabilities. Cloud-based software and assay design are employed to support these functions, enabling integration with standard laboratory equipment.
ChromaCode offers HDPCR Technology, ChromaCode Cloud, and Reagent Kits.
ChromaCode has 10 investors. Key investors include Caltech, Shimadzu Corporation, Global Brain, Northpond Ventures, and Windham Capital Partners.